Welcome to our dedicated page for GridAI Tech SEC filings (Ticker: GRDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GridAI Technologies Corp. filings document the formal reporting record for a Nasdaq Capital Market issuer that shifted from Entero Therapeutics into a diversified technology and life sciences company after the Grid AI acquisition. The filings identify GRDX common stock, material-event reports, operating and financial results, capital-structure matters, governance disclosures, shareholder voting matters, risk factors, and material agreements.
Recent 8-K disclosures also record Nasdaq periodic-reporting compliance matters tied to a delayed Form 10-K and the subsequent closure of that issue, as well as direct financial-obligation events under a revolving loan agreement. The filing record connects the company's energy-orchestration operations, legacy gastrointestinal therapeutics activities, financing arrangements, and public-company reporting obligations.
GridAI Technologies Corp. registers 1,306,165 shares of common stock for resale, representing shares issuable upon exercise of outstanding Common Warrants. The resale is by selling stockholders; the company will not receive proceeds from those resales but will receive proceeds if the Common Warrants are exercised for cash. The company’s common stock trades on Nasdaq under the symbol GRDX and had a last reported sale price of $5.93 on June 4, 2026. Financial context: as of March 31, 2026 the company held approximately $386,000 in cash, an accumulated deficit of $212.1M and a working capital deficit of $13.7M. Independent auditors included explanatory going concern language. The prospectus discloses the private placement that issued Pre-Funded Warrants and Common Warrants and states the Company completed financings on May 18, 2026 providing aggregate gross proceeds of approximately $7.8M, with $3.6M received at closings.
Syage Jack reported acquisition or exercise transactions in this Form 4 filing.
GridAI Technologies Corp. director Jack Syage reported an equity grant on Form 4. On January 1, 2026, he was awarded 40,000 restricted stock units that are settled in common shares with par value $0.0001 per share. The footnote states these RSUs vested immediately upon issuance, giving Syage direct ownership of 40,000 shares after the transaction. This is a compensation-related award rather than an open-market purchase or sale.
Syage Jack reported acquisition or exercise transactions in this Form 4 filing.
GridAI Technologies Corp. director Jack Syage reported an equity grant on Form 4. On January 1, 2026, he was awarded 40,000 restricted stock units that are settled in common shares with par value $0.0001 per share. The footnote states these RSUs vested immediately upon issuance, giving Syage direct ownership of 40,000 shares after the transaction. This is a compensation-related award rather than an open-market purchase or sale.
GridAI Technologies Corp. is registering 6,204,920 shares of common stock for resale by existing investors, including shares issuable from pre-funded and common warrants issued in May 2026 private placements. The company is not selling shares itself and will only receive cash if warrants are exercised.
GridAI operates AI-focused energy orchestration software through Grid AI Corp. and continues legacy Adrulipase drug development, but has generated limited revenue and remains loss-making. As of March 31, 2026, it held about $386,000 in cash, a working capital deficit of $13.7 million and an accumulated deficit of $212.1 million, and auditors have raised substantial doubt about its ability to continue as a going concern.
Recent financings on May 18, 2026 provided approximately $7.8 million in gross proceeds, which management expects to fund operations into the third quarter of 2026. GridAI is evaluating strategic options, including potential mergers, reverse mergers, asset sales, wind-down or bankruptcy, and plans to seek additional capital, including funding for a potential Phase 3 trial of Adrulipase.
GridAI Technologies Corp. reported a larger quarterly loss and raised doubt about its ability to continue as a going concern. For the three months ended March 31, 2026, the company generated revenue of $38,208 but posted a net loss of $3,438,702, or $0.82 per share attributable to common shareholders.
Cash and cash equivalents were $385,542 against total current liabilities of $16,231,727, and operating activities used $1,786,751 of cash in the quarter. Total assets were $47,965,678, including $24,118,676 of goodwill and $21,262,575 of definite-lived intangibles, while accumulated deficit reached $212,105,618.
Management explicitly states that recurring losses, negative operating cash flows, minimal cash, and reliance on raising new equity or debt create substantial doubt about continuing as a going concern for at least one year. The company is exploring strategic options, including mergers, sales, or even liquidation, but notes there is no assurance any transaction or financing will be completed.
GridAI Technologies Corp. reported a larger quarterly loss and raised doubt about its ability to continue as a going concern. For the three months ended March 31, 2026, the company generated revenue of $38,208 but posted a net loss of $3,438,702, or $0.82 per share attributable to common shareholders.
Cash and cash equivalents were $385,542 against total current liabilities of $16,231,727, and operating activities used $1,786,751 of cash in the quarter. Total assets were $47,965,678, including $24,118,676 of goodwill and $21,262,575 of definite-lived intangibles, while accumulated deficit reached $212,105,618.
Management explicitly states that recurring losses, negative operating cash flows, minimal cash, and reliance on raising new equity or debt create substantial doubt about continuing as a going concern for at least one year. The company is exploring strategic options, including mergers, sales, or even liquidation, but notes there is no assurance any transaction or financing will be completed.
GridAI Technologies Corp. entered a Debt Settlement and Subscription Agreement with its lender to resolve a default under a revolving loan. The lender had demanded $1,014,675 after the January 31, 2026 maturity passed without repayment. GridAI will pay $800,000 in cash, covering $700,000 of principal and $100,000 of accrued interest, and will issue 71,482 common shares at a deemed price of $3.25 per share to satisfy remaining accrued interest of $232,315.
GridAI Technologies Corp. entered a Debt Settlement and Subscription Agreement with its lender to resolve a default under a revolving loan. The lender had demanded $1,014,675 after the January 31, 2026 maturity passed without repayment. GridAI will pay $800,000 in cash, covering $700,000 of principal and $100,000 of accrued interest, and will issue 71,482 common shares at a deemed price of $3.25 per share to satisfy remaining accrued interest of $232,315.
GridAI Technologies Corp. notified the SEC it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 because completion of the annual Form 10-K for the year ended December 31, 2025 is delayed. The company expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date and signed this notification on May 15, 2026.
GridAI Technologies Corp. notified the SEC it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 because completion of the annual Form 10-K for the year ended December 31, 2025 is delayed. The company expects to file the Form 10-Q no later than the fifth calendar day following the prescribed due date and signed this notification on May 15, 2026.
GridAI Technologies Corp. entered into two private placement financings to raise equity-linked capital. A $2.54 million financing will issue 74,000 common shares, Pre-Funded Warrants for 1,196,001 shares, and Common Warrants for 1,270,001 shares at a combined purchase price of $2.00 per share or Pre-Funded Warrant plus Common Warrant. A separate $5.25 million financing will issue 87,260 common shares, Pre-Funded Warrants for 1,745,199 shares, and Common Warrants for 1,832,459 shares at $2.865 per unit, with 20% of proceeds paid at closing and 80% upon SEC effectiveness of a resale registration statement. All Pre-Funded Warrants are exercisable at $0.00001 per share with no expiration, and the related Common Warrants carry multi-year terms and specified exercise prices, subject to beneficial ownership limits and customary registration rights.
GridAI Technologies Corp. entered into two private placement financings to raise equity-linked capital. A $2.54 million financing will issue 74,000 common shares, Pre-Funded Warrants for 1,196,001 shares, and Common Warrants for 1,270,001 shares at a combined purchase price of $2.00 per share or Pre-Funded Warrant plus Common Warrant. A separate $5.25 million financing will issue 87,260 common shares, Pre-Funded Warrants for 1,745,199 shares, and Common Warrants for 1,832,459 shares at $2.865 per unit, with 20% of proceeds paid at closing and 80% upon SEC effectiveness of a resale registration statement. All Pre-Funded Warrants are exercisable at $0.00001 per share with no expiration, and the related Common Warrants carry multi-year terms and specified exercise prices, subject to beneficial ownership limits and customary registration rights.
GridAI Technologies Corp. reported that it has regained compliance with Nasdaq listing requirements after a brief filing delay. Nasdaq had notified the company on April 22, 2026 that it was not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the period ended December 31, 2025 was late. GridAI filed the Form 10-K on May 1, 2026, and on May 4, 2026 Nasdaq confirmed the company was back in compliance and closed the matter.
GridAI Technologies Corp. reported that it has regained compliance with Nasdaq listing requirements after a brief filing delay. Nasdaq had notified the company on April 22, 2026 that it was not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the period ended December 31, 2025 was late. GridAI filed the Form 10-K on May 1, 2026, and on May 4, 2026 Nasdaq confirmed the company was back in compliance and closed the matter.
GridAI Technologies Corp. filed its annual report outlining a strategic shift into AI-focused energy orchestration software while retaining its Adrulipase drug program. The company acquired Grid AI Corp. and 75% of AMPX, rebranded from Entero Therapeutics, and now centers on software for AI data centers and legacy biopharma R&D.
Grid AI’s platforms are early stage with minimal revenue and no commercial deployment yet for its AI data center solution. Adrulipase remains the main drug asset but had no active trials in 2025. At December 31, 2025, cash was about $0.9 million against an accumulated deficit of roughly $208.8 million, and auditors raised substantial doubt about continuing as a going concern.
The company defaulted on an 18% revolving loan and is exploring strategic alternatives, including potential merger, sale, wind-down or bankruptcy, while also managing past and current Nasdaq listing compliance issues. Only two parent-level employees remain, underscoring the scale-back as GridAI pursues a high-risk turnaround around its AI energy orchestration platform.
GridAI Technologies Corp. filed its annual report outlining a strategic shift into AI-focused energy orchestration software while retaining its Adrulipase drug program. The company acquired Grid AI Corp. and 75% of AMPX, rebranded from Entero Therapeutics, and now centers on software for AI data centers and legacy biopharma R&D.
Grid AI’s platforms are early stage with minimal revenue and no commercial deployment yet for its AI data center solution. Adrulipase remains the main drug asset but had no active trials in 2025. At December 31, 2025, cash was about $0.9 million against an accumulated deficit of roughly $208.8 million, and auditors raised substantial doubt about continuing as a going concern.
The company defaulted on an 18% revolving loan and is exploring strategic alternatives, including potential merger, sale, wind-down or bankruptcy, while also managing past and current Nasdaq listing compliance issues. Only two parent-level employees remain, underscoring the scale-back as GridAI pursues a high-risk turnaround around its AI energy orchestration platform.
GridAI Technologies Corp. reported receiving a notice from Nasdaq on April 22, 2026 stating it is not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the year ended December 31, 2025 has not yet been filed. The company has until June 22, 2026 to submit a plan to regain compliance, and Nasdaq may grant an extension through October 12, 2026 if the plan is accepted. GridAI attributes the delay to complexity in reviewing the accounting treatment and other information related to its recent acquisition of Grid AI Corp. The company plans to file the 10-K as soon as possible and submit a compliance plan, but cautions there is no assurance Nasdaq will accept the plan or that it will maintain compliance with Nasdaq requirements in the future.
GridAI Technologies Corp. reported receiving a notice from Nasdaq on April 22, 2026 stating it is not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the year ended December 31, 2025 has not yet been filed. The company has until June 22, 2026 to submit a plan to regain compliance, and Nasdaq may grant an extension through October 12, 2026 if the plan is accepted. GridAI attributes the delay to complexity in reviewing the accounting treatment and other information related to its recent acquisition of Grid AI Corp. The company plans to file the 10-K as soon as possible and submit a compliance plan, but cautions there is no assurance Nasdaq will accept the plan or that it will maintain compliance with Nasdaq requirements in the future.